Japan Zolbetuximab Filing Heats Up CLDN18.2 Competition

US, EU, China Filings Also Expected

 
• By Lisa Takagi

Astellas says its first approval filing globally for zolbetuximab - in Japan for gastric cancer - came faster than expected, as Scrip takes a look at the latest status of other CLDN18.2-targeting candidates in late clinical trials.

As Zolbetuximab reaches for approval, it awaits fierce competition for CLDN18.2-targeting drugs.
With first filing, zolbetuximab appears to be leading leading fierce global competition for CLDN18.2-targeting drugs. • Source: Shutterstock

More from Anticancer

More from Therapy Areas